CRISPR Therapeutics AG (CRSP) Cash & Equivalents (2015 - 2026)

CRISPR Therapeutics AG has disclosed Cash & Equivalents across 12 years of filings, most recently posting $423.3 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $423.3 million, up 79.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $423.3 million (up 79.99% YoY), and the FY2025 annual result was $347.6 million, changed N/A from the prior year.
• Cash & Equivalents came in at $423.3 million for Q1 2026 at CRISPR Therapeutics AG, up from $347.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $707.4 million in Q1 2024 to a low of $193.6 million in Q2 2025.
• The 5-year median for Cash & Equivalents is $406.4 million (2023), against an average of $406.1 million.
• Across the five-year window, Cash & Equivalents slumped 77.04% in 2022 and jumped 105.4% in 2024, its largest moves.
• CRISPR Therapeutics AG's Cash & Equivalents stood at $211.9 million in 2022, then soared by 83.82% to $389.5 million in 2023, then tumbled by 42.06% to $225.7 million in 2024, then jumped by 54.01% to $347.6 million in 2025, then gained by 21.79% to $423.3 million in 2026.
• The last three Cash & Equivalents figures came in at $423.3 million (Q1 2026), $347.6 million (Q4 2025), and $286.5 million (Q3 2025), per Business Quant data.